CuraChik (De Lamballerie), 2008 NCT00391313
chloroquine and derivatives (n=27) vs. placebo (n=27)
randomized controlled trial
high risk of bias
chloroquine
chloroquine 600 mg at day 1, 600 mg at days 2 and 3, and 300 mg at days 4 and 5
placebo
infections other than COVID-19
double-blind
French Reunion Island
Peymani, 2016
chloroquine and derivatives (n=6) vs. placebo (n=4)
randomized controlled trial
high risk of bias
chloroquine 150 mg/day for 8 weeks
placebo
infections other than COVID-19
double-blind
Iran
Borges, 2013
chloroquine and derivatives (n=63) vs. placebo (n=66)
randomized controlled trial
some concerns about risk of bias
chloroquine 600 mg/day for three days
placebo
infections other than COVID-19
Brazil
Paton, 2011 NCT01078779
chloroquine and derivatives (n=757) vs. placebo (n=749)
randomized controlled trial
low risk of bias
chloroquine
chloroquine phosphate (500 mg/day for 1 week, then once a week to complete 12 weeks)
placebo
infections other than COVID-19
double-blind
Singapore
Tricou, 2010
chloroquine and derivatives (n=278) vs. placebo (n=276)
randomized controlled trial
low risk of bias
600 mg D1-2, 300 mg D3
placebo
infections other than COVID-19
double-blind
Viet Nam